Why the study?
Treatment adherence and target control rates of blood pressure and glucose associate with prognosis, prompting investigation of postdischarge pharmaceutical care efficacy.
Does postdischarge pharmaceutical care improve 3-month medication adherence in patients with combined T2DM and hypertension?
Does postdischarge pharmaceutical care improve 3-month medication adherence in patients with combined T2DM and hypertension?
A postdischarge pharmaceutical care program utilizing clinical pharmacists and digital communication improves medication adherence in patients with T2DM and hypertension.
Background: The rates of treatment adherence and treat-to-target rates of blood pressure and blood glucose-related indexes in patients with hypertension and type 2 diabetes mellitus (T2DM) are associated with prognosis. This study aimed to investigate the efficacy of pharmaceutical care postdischarge for treatment adherence in hypertensive patients with type 2 diabetes mellitus (T2DM). Methods: This was a randomized controlled trial of patients with combined T2DM and hypertension treated between January and May 2018. Pharmaceutical care included free access to a clinical pharmacist, education material, a WeChat account for live discussion, and a telephone follow-up. The primary endpoint was the 3-month medication adherence. The secondary endpoints included the achieving levels of target rates and values of fasting plasma glucose (FPG), 2 h postprandial glucose (2hPG), and hemoglobin A1c (HbA1c) and the rates of reaching the achieving target rate of blood pressure target <130/80. Conclusion: The postdischarge pharmaceutical care program in patients with T2DM and hypertension improves medication adherence.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: